TA-CIN; HPV16 L2/E6/E7 proteins
Cat# : THP-0190
| Cat#: |
THP-0190 |
| Product Name: |
TA-CIN; HPV16 L2/E6/E7 proteins |
| Description: |
The product is a subunit vaccine antigen comprising L2/E6/E7 proteins from Human Papillomavirus (HPV16). |
| Sequences: |
Not Available |
| Species: |
Human |
| Molecular Weight: |
Not Available |
| Cas No: |
Not Available |
| Formula: |
Not Available |
| Endotoxin Level: |
<0.001 EU per 1 μg of the peptide by the LAL method |
| Drug Name: |
TA-CIN |
| Applications: |
Investigated for use/treatment in cervical dysplasia/cancer. |
| Examples of Clinical Use: |
Cervical dysplasia/cancer |
| Pharmacodynamics: |
Not Available |
| Mechanism of action: |
TA-CIN is targeted at patients with cervical dysplasia (pre-invasive cervical disease), thus potentially preventing the onset of invasive cervical cancer. The initial product candidate for clinical trials is a genetically engineered fusion of three proteins from HPV 16 known to play a role in the progression of cervical disease. |
| Affected organisms: |
Not Available |
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products
without prior written approval from Creative BioMart.
